Simvastatin was cost-effective across a broad range of risk and age groups

March 2007
ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p50
Academic Journal
The article reports on a study aimed at determining the effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. The cost-effectiveness study using a Markov model was conducted on 20,536 patients in the age group 40 to 80 years. It concluded that lifetime generic simvastatin was cost-effective in patients of different ages with a range of vascular risks.


Related Articles

  • Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. Griffin, SC; Barber, A; Manaca, A; Sculpher, MJ; Thompson, SG; Buxton, MJ; Hemingway, H // BMJ: British Medical Journal (International Edition);3/24/2007, Vol. 334 Issue 7594, p624 

    ABSTRACT Objective To assess whether revascularisation that is considered to be clinically appropriate is also cost effective. Design Prospective observational study comparing cost effectiveness of coronary artery bypass grafting, percutaneous coronary intervention, or medical management within...

  • Optimal Treatment of Acute Coronary Syndromes – An Evolving Strategy. Boden, William E.; McKay, Raymond G. // New England Journal of Medicine;06/21/2001, Vol. 344 Issue 25, p1939 

    The article discusses several studies which offer information on the benefits of pharmacologic therapy and percutaneous intervention for patients suffering from acute coronary syndromes. One of the studies explored the effectiveness of the intravenous administration of the glycoprotein IIb/IIIa...

  • CHAMPION PCI: Cangrelor not superior to clopidogrel in patients undergoing PCI.  // Hem/Onc Today;12/10/2009, Vol. 10 Issue 23, p42 

    The article discusses the findings from a phase-3 study which demonstrated that cangrelor did not lower a composite endpoint of death, myocardial infarction (MI) or ischemia-driven revascularization against clopidogrel, presented by Robert A. Harrington at the American Heart Association...

  • Invasive therapy warranted among elderly with CAD.  // PharmacoEconomics & Outcomes News;1/29/2005, Issue 470, p6 

    Presents the results of a study on the cost effectiveness of using an invasive therapy in treating elderly patients with chronic symptomatic coronary artery disease. Use of an economic analysis model of invasive therapy which includes coronary angiography followed by revascularization;...

  • Urgent revascularization with PCI was more cost-effective than CABG in medically refractory, high-risk myocardial ischemia.  // ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p49 

    The article reports on a research study aimed to find out the cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. About 445 patients who has medically refractory myocardial ischemia were studied. The study...

  • Heart Drug May Benefit HD Patients.  // Renal & Urology News;Sep2009, Vol. 8 Issue 9, p34 

    The article presents a study on anti-angina drug, Oral Nicorandil in hemodialysis patients led by Masato Nishimura of Toujinkai Hospital in Kyoto, Japan. It notes that 129 HD patients who underwent percutaneous coronary artery intervention and complete coronary revascularization are the subjects...

  • Miniaturized versus conventional cardiopulmonary bypass in high-risk patients undergoing coronary artery bypass surgery. Koivisto, Simo-Pekka; Wistbacka, Jan-Ola; Rimpiläinen, Riikka; Nissinen, Juha; Loponen, Pertti; Teittinen, Kari; Biancari, Fausto // Perfusion;Mar2010, Vol. 25 Issue 2, p65 

    Objective: To review our results with the use of miniaturized cardiopulmonary bypass (Mini-CPB) versus conventional cardiopulmonary bypass (C-CPB) in high-risk patients (additive EuroSCORE≥6) who have undergone coronary artery bypass graft surgery (CABG). Patients and methods: This study...

  • Impact of avoiding cardiopulmonary bypass for coronary surgery on perioperative cardiac enzyme release and survival Kuduvalli, Manoj; Newall, Nick; Stott, Anthony; Grayson, Antony D.; Fabri, Brian M. // European Journal of Cardio-Thoracic Surgery;May2006, Vol. 29 Issue 5, p729 

    Abstract: Objective: This study examines the association between avoiding the use of cardiopulmonary bypass (CPB) for coronary surgery and postoperative cardiac enzyme (CE) release, and its subsequent impact on survival. Methods: Between January 1999 and September 2002, 3734 consecutive patients...

  • Early revascularisation of no benefit in mild heart attacks. Josefson, Deborah // BMJ: British Medical Journal (International Edition);06/27/98, Vol. 316 Issue 7149, p1928 

    Provides information on a study involving a number of patients who were assigned to conservative management for heart attacks, which is superior to early revascularisation. What conservative management consisted of; Details on the treatment of the patients; Percentage of patients who underwent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics